Health knowledge made personal
Join this community!
› Share page:
Search posts:

Chimeric Anti-human ROR1 Monoclonal Antibodies

Posted Aug 23 2010 5:00pm

Description of Invention:
Available for licensing are mouse anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibodies (mAbs). ROR1 is a signature cell surface antigen for B-cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) cells, two incurable B-cell malignancies that are newly diagnosed in approximately 15,000 and 3,500 patients per year, respectively, in the United States. Currently, there are no therapeutic mAbs that specifically target B-CLL or MCL cells. Anti-ROR1 mAbs may be linked to chemical drugs or biological toxins thus providing cytotoxic delivery to malignant B-cells and not normal cells. Additionally, these antibodies can be fused to radioisotopes and can be used to diagnose B-CLL and MCL malignancies.

  • B-CLL and MCL antibody therapeutics
  • Method to diagnose B-CLL and MCL

Selective targeting to malignant B-CLL and MCL cells

Development Status:
The technology is currently in the pre-clinical stage of development.

Christoph Rader (NCI)
Sivasubramanian Baskar (NCI)

Patent Status:
HHS, Reference No. E-097-2009/0
PCT, Application No. PCT/US10/32208 filed 23 Apr 2010

Relevant Publication:
  1. S Baskar et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008 Jan 15;14(2):396-404. [ PubMed: 18223214 ]
  2. M Hudecek et al. The B-cell tumor associated antigen ROR1 can be targeted with T-cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010 Aug 11; Epub ahead of print. [ PubMed: 20702778 ]

Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Center for Cancer Research, Experimental Transplantation and Immunology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize anti-ROR1 mAbs, antibody-drug conjugates, radioimmunoconjugates, bispecific antibodies, and other therapeutic or diagnostic modalities. Please contact John D. Hewes, Ph.D. at 301-435-3121 or for more information. Click here to view the NCI collaborative opportunity announcement.

Cancer - Diagnostics
Cancer - Therapeutics

For Licensing Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-4633
Fax: 301-402-0220

Ref No: 2151

Updated: 08/2010

Post a comment
Write a comment:

Related Searches